Security National Bank increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 11.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 75,491 shares of the company’s stock after acquiring an additional 7,582 shares during the quarter. Merck & Co., Inc. comprises 1.7% of Security National Bank’s investment portfolio, making the stock its 24th biggest position. Security National Bank’s holdings in Merck & Co., Inc. were worth $5,820,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Catalyst Private Wealth LLC bought a new stake in shares of Merck & Co., Inc. during the 3rd quarter worth about $25,000. Flagship Private Wealth LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $27,000. Financial Avengers Inc. bought a new stake in Merck & Co., Inc. in the 4th quarter valued at about $28,000. Joseph P. Lucia & Associates LLC bought a new stake in Merck & Co., Inc. in the 4th quarter valued at about $29,000. Finally, Curi Capital bought a new stake in Merck & Co., Inc. in the 4th quarter valued at about $29,000. 72.86% of the stock is owned by institutional investors and hedge funds.
Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Merck & Co., Inc. in a report on Friday, February 5th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $95.92.
Shares of NYSE:MRK traded down $0.22 during midday trading on Thursday, hitting $75.90. The stock had a trading volume of 170,483 shares, compared to its average volume of 11,986,551. The company’s 50-day moving average price is $75.36 and its 200-day moving average price is $79.05. The company has a market capitalization of $192.05 billion, a P/E ratio of 16.84, a price-to-earnings-growth ratio of 1.89 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.30 and a debt-to-equity ratio of 0.90. Merck & Co., Inc. has a fifty-two week low of $71.71 and a fifty-two week high of $87.80.
Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Wednesday, February 3rd. The company reported $1.32 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.06). The firm had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.65 billion. Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. Merck & Co., Inc.’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.16 earnings per share. Research analysts expect that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 7th. Investors of record on Monday, March 15th were given a dividend of $0.65 per share. This represents a $2.60 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date was Friday, March 12th. Merck & Co., Inc.’s dividend payout ratio is 50.10%.
Merck & Co., Inc. Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as and vaccine products.
Read More: Balanced Fund
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.